Solexa, Inc. Announces Major Sequencing Progress And Targets Whole Human Genome 
10/19/2005 5:13:23 PM

HAYWARD, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--Oct. 18, 2005--Solexa, Inc. (Nasdaq:SLXA) today announced that its scientists have sequenced a human bacterial artificial chromosome (BAC), an important milestone demonstrating that Solexa's reversible-terminator chemistry and Clonal Single-Molecule Array(TM) technology can be applied to resequence human DNA. The results of this project, which were presented today during the GSAC 2005 Genomes, Medicine and the Environment Conference, demonstrate that Solexa's platform can achieve the data quality, read length and coverage uniformity required for economical and rapid resequencing of human DNA. Solexa expects its instrument system to be the first to dramatically reduce the cost, while also increasing the speed, of DNA sequencing. In particular, Solexa expects to be the first to deliver whole human genome sequencing at $100,000 per genome.